Addex Therapeutics Ltd (NASDAQ:ADXN) Sees Significant Decrease in Short Interest

Addex Therapeutics Ltd (NASDAQ:ADXN) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 1,700 shares, a decrease of 39.3% from the June 30th total of 2,800 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 8,100 shares, the days-to-cover ratio is currently 0.2 days.

Addex Therapeutics Stock Performance

Shares of Addex Therapeutics stock opened at $8.00 on Friday. Addex Therapeutics has a one year low of $5.00 and a one year high of $27.90. The business has a 50-day simple moving average of $8.36 and a 200-day simple moving average of $10.77. The company has a market cap of $8.48 million, a PE ratio of -0.46 and a beta of 1.77.

Addex Therapeutics (NASDAQ:ADXN) last issued its earnings results on Thursday, June 6th. The company reported ($1.37) earnings per share (EPS) for the quarter. The company had revenue of $0.27 million during the quarter. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. On average, sell-side analysts predict that Addex Therapeutics will post -11.8 earnings per share for the current fiscal year.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.